Loading...
•
Mar 31, 2021
Ultragenyx Q1 2021 Earnings Report
Reported financial results for Q1 2021 and reaffirmed the financial guidance for 2021.
Key Takeaways
Ultragenyx reported a total revenue of $99.4 million for the first quarter of 2021, with Crysvita revenue reaching $42.1 million. The company reaffirmed its 2021 Crysvita revenue guidance of $180 million to $190 million. Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States.
First quarter 2021 total revenue of $99.4 million.
Crysvita revenue to Ultragenyx of $42.1 million.
2021 Crysvita revenue in Ultragenyx territories guidance of $180 million to $190 million reaffirmed.
Strong Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States
Revenue by Segment
Forward Guidance
The company reaffirmed the 2021 guidance range for Crysvita that was provided at the beginning of the year. This range is $180 million to $190 million and includes the North American profit share region and the other regions where product sales are recognized.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...